Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation.
Antibody microarrays are among the novel class of rapidly emerging proteomic technologies that will allow us to efficiently perform specific diagnoses and proteomic analysis. Recombinant antibody fragments are especially suited for this approach but their stability is often a limiting factor. Camelids produce functional antibodies devoid of light chains (HCAbs) of which the single N-terminal domain is fully capable of antigen binding. When produced as an independent domain, these so-called single domain antibody fragments (sdAbs) have several advantages for biotechnological applications thanks to their unique properties of size (15 kDa), stability, solubility, and expression yield. These features should allow sdAbs to outperform other antibody formats in a number of applications, notably as capture molecules for antibody arrays. In this study, we have produced antibody microarrays using direct and oriented immobilization of sdAbs, produced in crude bacterial lysates, to generate a proof-of-principle of a high-throughput compatible array design. Several sdAb immobilization strategies have been explored. Immobilization of in vivo biotinylated sdAbs by direct spotting of bacterial lysate on streptavidin and sandwich detection was developed to achieve high sensitivity and specificity, whereas immobilization of "multi-tagged" sdAbs via anti-tag antibodies and a direct labeled sample detection strategy was optimized for the design of high-density antibody arrays for high-throughput proteomics and identification of potential biomarkers.
Even-Desrumeaux
Klervi
K
INSERM U624, 163 avenue de Luminy-case 915, 13288 Marseille Cedex 09, France.
Baty
Daniel
D
Chames
Patrick
P
D000906:Antibodies / Q000378:metabolism*; D000941:Antigens / Q000276:immunology; D001419:Bacteria / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000276:immunology; D019921:Biotinylation; D002272:Carcinoembryonic Antigen / Q000276:immunology; D002457:Cell Extracts; D002460:Cell Line; D045424:Complex Mixtures / Q000378:metabolism*; D003362:Cost-Benefit Analysis; D003593:Cytoplasm / Q000378:metabolism; D004926:Escherichia coli / Q000378:metabolism; D057166:High-Throughput Screening Assays / Q000191:economics* / Q000379:methods*; D006801:Humans; D055767:Immobilized Proteins / Q000378:metabolism*; D007118:Immunoassay; D040081:Protein Array Analysis / Q000191:economics*; D000095983:Bacterial Lysates
D000906:Antibodies; D000941:Antigens; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D002457:Cell Extracts; D045424:Complex Mixtures; D055767:Immobilized Proteins; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates